Evolutionary Tree Capital Management LLC Takes $1.83 Million Position in Abbott Laboratories $ABT

Evolutionary Tree Capital Management LLC bought a new position in Abbott Laboratories (NYSE:ABT) during the 1st quarter, HoldingsChannel reports. The fund bought 17,867 shares of the healthcare product maker’s stock, valued at approximately $1,834,000. Abbott Laboratories accounts for about 3.4% of Evolutionary Tree Capital Management LLC’s holdings, making the stock its 15th biggest holding.

A number of other hedge funds have also made changes to their positions in the company. Nia Impact Advisors LLC boosted its position in Abbott Laboratories by 2.2% in the second quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker’s stock valued at $504,000 after buying an additional 79 shares in the last quarter. Clayton Financial Group LLC increased its holdings in shares of Abbott Laboratories by 1.4% during the fourth quarter. Clayton Financial Group LLC now owns 6,217 shares of the healthcare product maker’s stock worth $779,000 after buying an additional 84 shares in the last quarter. Raleigh Capital Management Inc. raised its stake in shares of Abbott Laboratories by 3.9% in the fourth quarter. Raleigh Capital Management Inc. now owns 2,287 shares of the healthcare product maker’s stock valued at $287,000 after acquiring an additional 85 shares during the last quarter. Riggs Asset Managment Co. Inc. raised its stake in shares of Abbott Laboratories by 9.3% in the second quarter. Riggs Asset Managment Co. Inc. now owns 1,031 shares of the healthcare product maker’s stock valued at $140,000 after acquiring an additional 88 shares during the last quarter. Finally, BridgePort Financial Solutions LLC boosted its holdings in shares of Abbott Laboratories by 3.7% in the 4th quarter. BridgePort Financial Solutions LLC now owns 2,591 shares of the healthcare product maker’s stock worth $325,000 after acquiring an additional 92 shares in the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Wall Street Analysts Forecast Growth

ABT has been the subject of a number of recent analyst reports. Argus dropped their price target on Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating for the company in a report on Tuesday, April 21st. Royal Bank Of Canada reissued an “outperform” rating and issued a $130.00 price objective on shares of Abbott Laboratories in a research note on Friday, July 17th. TD Cowen restated a “buy” rating and set a $115.00 target price on shares of Abbott Laboratories in a report on Friday, July 17th. Leerink Partners lowered their target price on Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating for the company in a research note on Tuesday, April 21st. Finally, Wells Fargo & Company upped their price target on shares of Abbott Laboratories from $109.00 to $112.00 and gave the stock an “overweight” rating in a research report on Friday, July 17th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $118.17.

Abbott Laboratories Stock Up 0.4%

NYSE:ABT opened at $105.99 on Friday. The company has a market cap of $183.40 billion, a price-to-earnings ratio of 34.30, a P/E/G ratio of 2.04 and a beta of 0.61. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.01 and a current ratio of 1.38. The stock’s fifty day moving average price is $93.45 and its two-hundred day moving average price is $100.62. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $137.49.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, beating the consensus estimate of $1.28 by $0.03. The company had revenue of $12.59 billion during the quarter, compared to analysts’ expectations of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The business’s revenue for the quarter was up 13.0% on a year-over-year basis. During the same period last year, the firm earned $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, analysts anticipate that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 81.55%.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Raised earnings estimate: Erste Group Bank increased its FY2026 EPS forecast for Abbott to $5.52 from $5.47, matching the broader consensus estimate. The revision reinforces expectations for continued earnings growth. Erste Group raises Abbott earnings estimate
• Positive Sentiment: Recent results remain supportive: Abbott’s latest quarterly report exceeded analyst expectations for both earnings and revenue, with revenue rising 13% year over year. Management also provided FY2026 EPS guidance of $5.45 to $5.60, supporting the positive earnings narrative.
• Positive Sentiment: Strategic diversification and income appeal: A comparison with Johnson & Johnson highlighted Abbott’s broad exposure to medical devices and diagnostics, strengthened by the Exact Sciences acquisition. Separately, analysts continue to identify ABT as an attractive Dividend Aristocrat for investors seeking recurring cash income. Abbott versus Johnson and Johnson comparison
• Neutral Sentiment: Healthcare-sector momentum: Strong performances from AbbVie and Guardant Health indicate continued investor interest in healthcare and diagnostics, but these companies’ results do not directly change Abbott’s fundamentals.
• Negative Sentiment: Valuation pressure: UBS lowered its expectations for Abbott’s stock price, potentially limiting upside and weighing on sentiment after the recent recovery. UBS lowers Abbott stock price expectations

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.